CO2018006473A2 - Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal - Google Patents

Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal

Info

Publication number
CO2018006473A2
CO2018006473A2 CONC2018/0006473A CO2018006473A CO2018006473A2 CO 2018006473 A2 CO2018006473 A2 CO 2018006473A2 CO 2018006473 A CO2018006473 A CO 2018006473A CO 2018006473 A2 CO2018006473 A2 CO 2018006473A2
Authority
CO
Colombia
Prior art keywords
cocristal
production
medication containing
crystal
medication
Prior art date
Application number
CONC2018/0006473A
Other languages
English (en)
Inventor
Koya Kimoto
Mitsuo Yamamoto
Masato Kitayama
Yasuhiro Sawai
Miyuki Hohokabe
Kentaro Iwata
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2018006473A2 publication Critical patent/CO2018006473A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención proporciona un cocristal de (S)-3-(1-((1-acriloilpirrolidin-3-il)oxi)isoquinolin-3-il)-1H-1,2,4-triazol-5(4H)-ona y un ácido orgánico capaz de formar un cocristal con el compuesto.
CONC2018/0006473A 2015-12-24 2018-06-22 Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal CO2018006473A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015252658 2015-12-24
PCT/JP2016/089224 WO2017111179A1 (en) 2015-12-24 2016-12-22 Cocrystal, production method thereof, and medicament containing cocrystal

Publications (1)

Publication Number Publication Date
CO2018006473A2 true CO2018006473A2 (es) 2018-07-10

Family

ID=57910088

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006473A CO2018006473A2 (es) 2015-12-24 2018-06-22 Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal

Country Status (25)

Country Link
US (1) US10836745B2 (es)
EP (1) EP3394045B1 (es)
JP (1) JP6876704B2 (es)
KR (1) KR20180095933A (es)
CN (1) CN108473467B (es)
AR (1) AR107132A1 (es)
AU (1) AU2016375899B2 (es)
CA (1) CA3009610C (es)
CL (1) CL2018001725A1 (es)
CO (1) CO2018006473A2 (es)
DK (1) DK3394045T3 (es)
EA (1) EA039213B1 (es)
EC (1) ECSP18055921A (es)
ES (1) ES2877089T3 (es)
HK (1) HK1256362A1 (es)
IL (1) IL260195A (es)
MX (1) MX2018007721A (es)
PH (1) PH12018501356A1 (es)
PL (1) PL3394045T3 (es)
SG (1) SG11201805331QA (es)
TN (1) TN2018000221A1 (es)
TW (1) TWI722080B (es)
UY (1) UY37046A (es)
WO (1) WO2017111179A1 (es)
ZA (1) ZA201804393B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200268027A1 (en) 2017-10-06 2020-08-27 Cargill, Incorporated Stabilized steviol glycoside compositions and uses thereof
CA3078200C (en) * 2017-10-06 2023-09-19 Cargill, Incorporated Steviol glycoside solubility enhancers
JP2022527518A (ja) 2019-04-06 2022-06-02 カーギル インコーポレイテッド 感覚改質剤
CN110818692B (zh) * 2019-11-08 2023-03-24 中国海洋大学 一种替加氟与丁香酸的共晶及其制备方法
TW202140425A (zh) * 2020-04-21 2021-11-01 健亞生物科技股份有限公司 硫酸羥氯喹之晶體

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ATE263163T1 (de) 1997-10-07 2004-04-15 Schering Corp Krytallinischer fungizider polymorph
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN101541618A (zh) 2007-02-28 2009-09-23 日本精工株式会社 倾斜式转向装置
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CA2781182A1 (en) 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
SG11201805331QA (en) 2018-07-30
BR112018012915A2 (pt) 2018-12-11
CL2018001725A1 (es) 2018-10-19
WO2017111179A1 (en) 2017-06-29
DK3394045T3 (da) 2021-08-16
UY37046A (es) 2017-07-31
ZA201804393B (en) 2019-09-25
US10836745B2 (en) 2020-11-17
CN108473467A (zh) 2018-08-31
AU2016375899B2 (en) 2021-05-13
EP3394045B1 (en) 2021-05-19
KR20180095933A (ko) 2018-08-28
PL3394045T3 (pl) 2021-09-27
CA3009610A1 (en) 2017-06-29
CA3009610C (en) 2024-02-13
IL260195A (en) 2018-07-31
TW201730181A (zh) 2017-09-01
JP6876704B2 (ja) 2021-05-26
EP3394045A1 (en) 2018-10-31
JP2019504025A (ja) 2019-02-14
US20170183326A1 (en) 2017-06-29
ECSP18055921A (es) 2018-10-31
MX2018007721A (es) 2018-08-15
EA039213B1 (ru) 2021-12-17
AU2016375899A1 (en) 2018-07-19
PH12018501356A1 (en) 2019-02-18
EA201891467A1 (ru) 2018-12-28
HK1256362A1 (zh) 2019-09-20
CN108473467B (zh) 2021-08-13
ES2877089T3 (es) 2021-11-16
TWI722080B (zh) 2021-03-21
TN2018000221A1 (en) 2019-10-04
AR107132A1 (es) 2018-03-21

Similar Documents

Publication Publication Date Title
CO2018006473A2 (es) Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CO2017001608A2 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
MA49287A (fr) Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CO2017010806A2 (es) Método para manufacturar compuesto novedoso que contiene nitrógeno o sal del mismo e intermediario de manufacturación del compuesto novedoso que contiene nitrógeno o sal del mismo
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
CL2016001745A1 (es) Ácido (s)-3'-metil-abscísico y ésteres del mismo
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
CO2019010117A2 (es) Proceso para la separación de isómeros ópticos de etilésteres racémicos del ácido 3-alquilpiperidin-carboxílico
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.
TH1701003495A (th) สารประกอบไตรอะโซโลไพริมิดีนและการใช้สารประกอบนี้
AR107790A1 (es) Formas sólidas de una tienopirimidindiona inhibidora de acc y métodos de producción de la misma
UA126152U (uk) Цис-2-(трифлуорометил)циклогексилметиламін
TH1701002897A (th) สารประกอบ n-((เฮท)แอริลเมธิล)-เฮเทโรแอริล-คาร์บอกแซมีดเป็นตัวยับยั้งพลาสมาแคลลิเครอิน
GB201705502D0 (en) Antimalarial medicine intermediates 2,4-diclorobenzoic acid synthesis
PL124556U1 (pl) Taśma identyfikacyjna
TH176870A (th) สารประกอบพิโคลิแนมีดที่มีฤทธิ์ฆ่ารา
TH1701004187A (th) อนุพันธ์ 4H-ไพร์โรโล[3,2-c]ไพริดิน-4-โอน